{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:35:49Z","timestamp":1790829349793,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.kint.2017.06.028","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T02:32:20Z","timestamp":1504233140000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease"],"prefix":"10.1016","volume":"93","author":[{"given":"Casey M.","family":"Rebholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Selvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron C.","family":"Hoogeveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2017.06.028_bib1","first-page":"1016","article-title":"Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages","volume":"147","author":"Liu","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2017.06.028_bib2","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399408000719","article-title":"Galectins: structure, function and therapeutic potential","volume":"10","author":"Yang","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.kint.2017.06.028_bib3","doi-asserted-by":"crossref","first-page":"20807","DOI":"10.1016\/S0021-9258(17)31891-4","article-title":"Galectins. Structure and function of a large family of animal lectins","volume":"269","author":"Barondes","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2017.06.028_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.kint.2017.06.028_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: a novel mediator of heart failure development and progression","volume":"11","author":"de Boer","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2017.06.028_bib6","doi-asserted-by":"crossref","first-page":"e003079","DOI":"10.1161\/JAHA.115.003079","article-title":"Galectin-3 and risk of heart failure and death in blacks and whites","volume":"5","author":"McEvoy","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2017.06.028_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2017.06.028_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2017.06.028_bib9","doi-asserted-by":"crossref","first-page":"e28952","DOI":"10.4103\/2251-9572.218694","article-title":"Galectin-3 serum levels are independently associated with microalbuminuria in chronic heart failure outpatients","volume":"5","author":"Iacoviello","year":"2016","journal-title":"Res Cardiovasc Med"},{"key":"10.1016\/j.kint.2017.06.028_bib10","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O'Seaghdha","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.06.028_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1053\/j.ajkd.2015.12.022","article-title":"Galectin-3 and soluble ST2 and kidney function decline in older adults: The Cardiovascular Health Study (CHS)","volume":"67","author":"Bansal","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/ATVBAHA.107.159160","article-title":"Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction","volume":"28","author":"Papaspyridonos","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2017.06.028_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/jim-2015-000041","article-title":"Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis?","volume":"64","author":"Aksan","year":"2016","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.kint.2017.06.028_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2017.06.028_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11906-013-0354-3","article-title":"Aldosterone mediates cardiac fibrosis in the setting of hypertension","volume":"15","author":"Azibani","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2017.06.028_bib16","doi-asserted-by":"crossref","first-page":"e95254","DOI":"10.1371\/journal.pone.0095254","article-title":"Aldosterone induced galectin-3 secretion in\u00a0vitro and in\u00a0vivo: from cells to humans","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.06.028_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin-3 in cardiac remodeling and heart failure","volume":"7","author":"de Boer","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.kint.2017.06.028_bib18","doi-asserted-by":"crossref","first-page":"F500","DOI":"10.1152\/ajprenal.00461.2014","article-title":"Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy","volume":"308","author":"Frenay","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2017.06.028_bib19","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","article-title":"GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death","volume":"115","author":"Streetly","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kint.2017.06.028_bib20","doi-asserted-by":"crossref","first-page":"e83481","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.06.028_bib21","doi-asserted-by":"crossref","first-page":"e18683","DOI":"10.1371\/journal.pone.0018683","article-title":"Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury","volume":"6","author":"Kolatsi-Joannou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.06.028_bib22","doi-asserted-by":"crossref","first-page":"24534","DOI":"10.1074\/jbc.M800006200","article-title":"Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site","volume":"283","author":"Kahsai","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2017.06.028_bib23","doi-asserted-by":"crossref","first-page":"e0166272","DOI":"10.1371\/journal.pone.0166272","article-title":"Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage","volume":"11","author":"Martinez-Martinez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.06.028_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000446376","article-title":"Galectin-3 in renal pathology: more than just an innocent bystander","volume":"43","author":"Desmedt","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.06.028_bib25","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2014010093","article-title":"Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies","volume":"26","author":"Drechsler","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.06.028_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/eurjhf\/hfs205","article-title":"Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT","volume":"15","author":"Anand","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2017.06.028_bib27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2014.02.021","article-title":"Identification of incident CKD stage 3 in research studies","volume":"64","author":"Grams","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2016.05.019","article-title":"DASH (Dietary Approaches to Stop Hypertension) diet and risk of subsequent kidney disease","volume":"68","author":"Rebholz","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib29","doi-asserted-by":"crossref","first-page":"e003192","DOI":"10.1161\/JAHA.116.003192","article-title":"Relationship of the American Heart Association's Impact Goals (Life's Simple 7) with risk of chronic kidney disease: results from the Atherosclerosis Risk in Communities (ARIC) Cohort Study","volume":"5","author":"Rebholz","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2017.06.028_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000443746","article-title":"Dietary acid load and incident chronic kidney disease: results from the ARIC study","volume":"42","author":"Rebholz","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.06.028_bib31","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1373\/clinchem.2014.229427","article-title":"Association of 1,5-anhydroglucitol with diabetes and microvascular conditions","volume":"60","author":"Selvin","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.kint.2017.06.028_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.aje.a115184","article-title":"The Atherosclerosis Risk in Communities (ARIC) study: design and objectives","volume":"129","year":"1989","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.kint.2017.06.028_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1515\/cclm-2013-0942","article-title":"Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments","volume":"52","author":"Gaze","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.kint.2017.06.028_bib34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2017.06.028_bib35","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2015.238873","article-title":"Recalibration of blood analytes over 25 years in the Atherosclerosis Risk in Communities Study: impact of recalibration on chronic kidney disease prevalence and incidence","volume":"61","author":"Parrinello","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.kint.2017.06.028_bib36","first-page":"496","article-title":"Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study","volume":"118","author":"Eckfeldt","year":"1994","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.kint.2017.06.028_bib37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/ajkd.2002.32765","article-title":"Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate","volume":"39","author":"Coresh","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an endpoint for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/kisup.2015.2","article-title":"United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease","volume":"5","author":"Collins","year":"2015","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2017.06.028_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.ajkd.2015.01.016","article-title":"Kidney Failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) study: comparing ascertainment of treated and untreated kidney failure in a cohort study","volume":"66","author":"Rebholz","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/CIRCHEARTFAILURE.111.963199","article-title":"Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria","volume":"5","author":"Rosamond","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kint.2017.06.028_bib42","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1515\/CCLM.2010.318","article-title":"First certified reference material for cystatin C in human serum ERM-DA471\/IFCC","volume":"48","author":"Grubb","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.kint.2017.06.028_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.06.028_bib44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.ajkd.2011.05.019","article-title":"Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values","volume":"58","author":"Inker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.06.028_bib45","doi-asserted-by":"crossref","first-page":"e68095","DOI":"10.1371\/journal.pone.0068095","article-title":"Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium","volume":"8","author":"Grove","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.06.028_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1037\/1082-989X.12.4.399","article-title":"Toward using confidence intervals to compare correlations","volume":"12","author":"Zou","year":"2007","journal-title":"Psychol Methods"},{"key":"10.1016\/j.kint.2017.06.028_bib47","series-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"key":"10.1016\/j.kint.2017.06.028_bib48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2017.06.028_bib49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817304970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817304970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T21:53:05Z","timestamp":1659390785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253817304970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0085253817304970"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2017.06.028","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2017.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}